GMP – Page 28 – Pharma.Tips

Equipment downtime due to cleaning during equipment changeover – cycle time reduction with compliance assurance

Reducing Equipment Downtime During Changeover Cleaning While Ensuring Compliance In pharmaceutical manufacturing, equipment downtime due to cleaning during equipment changeovers can significantly impact productivity and operational efficiency. Despite maintaining compliance…

Inadequate WHO GMP training during API sourcing – avoiding repeat WHO observations

Mitigating Risks from Inadequate WHO GMP Training in API Sourcing Inadequate WHO GMP training during API sourcing can lead to serious compliance issues that not only jeopardize product quality but…

API site WHO GMP risk during prequalification preparation – avoiding repeat WHO observations

Mitigating WHO GMP Risks During API Site Prequalification Preparation Pharmaceutical manufacturers, especially those dealing with Active Pharmaceutical Ingredients (APIs), must prioritize compliance to avoid audit failures and repeated observations from…

Documentation not aligned to WHO during prequalification preparation – WHO inspector expectations explained

Aligning Documentation with WHO Inspector Expectations in Prequalification Preparation In the dynamic landscape of pharmaceutical manufacturing, ensuring compliance with WHO standards during prequalification preparation is critical. The growing complexities of…

Equipment downtime due to cleaning during CPV review – validated efficiency improvement

“`html Addressing Equipment Downtime During CPV Review for Cleaning Efficiency In the pharmaceutical manufacturing landscape, cleaning validation during Continued Process Verification (CPV) can often lead to significant equipment downtime. This…

API site WHO GMP risk during WHO inspection – evidence pack for WHO audits

“`html Addressing WHO GMP Risk During Inspections: An Actionable Playbook for API Sites Regulatory inspections, particularly by the WHO, can unveil vulnerabilities that might compromise the integrity of a pharmaceutical…

API site WHO GMP risk during remediation planning – gap remediation roadmap

Effective Remediation Planning for WHO GMP Risks at API Sites Non-compliance with WHO GMP standards can pose significant risks to Active Pharmaceutical Ingredient (API) manufacturers, especially during remediation planning. This…

API site WHO GMP risk during internal gap assessment – avoiding repeat WHO observations

Navigating WHO GMP Risks in API Sites During Internal Gap Assessments Internal gap assessments at API sites are essential yet complex processes that critically determine compliance with WHO GMP standards.…

Extended cleaning duration during validation lifecycle – validated efficiency improvement

Addressing Extended Cleaning Duration During the Validation Lifecycle for Efficiency Improvement In pharmaceutical manufacturing, extended cleaning durations can significantly hinder operational efficiency, leading to potential compliance issues and costly downtime.…

WHO GMP gap identified during prequalification preparation – gap remediation roadmap

Addressing WHO GMP Gaps During Prequalification: A Comprehensive Remediation Roadmap Pharmaceutical manufacturers face constant scrutiny when preparing for WHO prequalification (PQ) evaluations, which assess compliance with Good Manufacturing Practices (GMP).…

Supplier WHO GMP non-compliance during WHO inspection – evidence pack for WHO audits

Addressing WHO GMP Non-Compliance during Inspections: A Practical Guide Pharmaceutical manufacturers face increasing scrutiny regarding compliance with Good Manufacturing Practices (GMP), especially during inspections by the World Health Organization (WHO).…

Documentation not aligned to WHO during prequalification preparation – gap remediation roadmap

Effective Remediation for Misaligned Documentation During WHO Prequalification In the pharmaceutical industry, misalignment of documentation with the World Health Organization (WHO) standards during prequalification can pose significant challenges, especially when…